Literature DB >> 15015068

The enigma of hyperparathyroidism in hypophosphatemic rickets.

Claus Peter Schmitt1, Otto Mehls.   

Abstract

Familial hypophosphatemic rickets (XLH) is caused by inactivating mutations of the cell surface metalloproteinase PHEX. It is characterized by low-normal serum levels of 1,25-dihydroxyvitamin D(3)[1,25(OH)(2)D(3)], normocalcemia, and hypophosphatemia. Hyperparathyroidism is regularly seen in patients treated with phosphate supplements, although circulating serum phosphate levels do not reach the normal range. The mechanism is unknown. Decreased serum concentrations of ionized calcium following phosphate supplements might contribute to the development of hyperparathyroidism. Secondary and even tertiary hyperparathyroidism can, however, be observed in patients who have never received phosphate treatment. This points to an abnormal regulation of production and/or degradation of parathyroid hormone (PTH). Recently, the expression of the PHEX gene in hypertrophied parathyroid glands of a patient with XLH has been reported. It is unclear whether the mutant PHEX gene can induce hyperparathyroidism by abnormal regulation of peptidases.

Entities:  

Mesh:

Year:  2004        PMID: 15015068     DOI: 10.1007/s00467-004-1443-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  52 in total

1.  Cardiovascular abnormalities in patients with X-linked hypophosphatemia.

Authors:  R Nehgme; J T Fahey; C Smith; T O Carpenter
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

2.  Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets.

Authors:  K C Moltz; A H Friedman; R A Nehgme; C S Kleinman; T O Carpenter
Journal:  Curr Opin Pediatr       Date:  2001-08       Impact factor: 2.856

3.  Tertiary hyperparathyroidism in X-linked hypophosphatemic rickets.

Authors:  C J Wu; Y M Song; W H Sheu
Journal:  Intern Med       Date:  2000-06       Impact factor: 1.271

4.  Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood.

Authors:  G P Mayer; J A Keaton; J G Hurst; J F Habener
Journal:  Endocrinology       Date:  1979-06       Impact factor: 4.736

5.  Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study.

Authors:  E D Hsi; L R Zukerberg; W I Yang; A Arnold
Journal:  J Clin Endocrinol Metab       Date:  1996-05       Impact factor: 5.958

6.  Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia.

Authors:  Yasuo Imanishi; Hideki Tahara; Nallasivam Palanisamy; Sarah Spitalny; Isidro B Salusky; William Goodman; Maria Luisa Brandi; Tilman B Drüeke; Emile Sarfati; Pablo Ureña; R S K Chaganti; Andrew Arnold
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

7.  p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.

Authors:  M Cozzolino; Y Lu; J Finch; E Slatopolsky; A S Dusso
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

8.  RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate.

Authors:  E Moallem; R Kilav; J Silver; T Naveh-Many
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

Review 9.  Guide-lines to the treatment of patients with X-linked hypophosphatemic rickets.

Authors:  G S Reusz
Journal:  Acta Biomed Ateneo Parmense       Date:  1995

Review 10.  Therapeutics of X-linked hypophosphatemic rickets.

Authors:  K Latta; S Hisano; J C Chan
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

View more
  8 in total

Review 1.  Clinical practice: diagnostic approach to the rachitic child.

Authors:  Jaishen Rajah; Kebashni Thandrayen; John M Pettifor
Journal:  Eur J Pediatr       Date:  2011-07-21       Impact factor: 3.183

2.  Growth in X-linked hypophosphatemic rickets.

Authors:  Gema Ariceta; Craig B Langman
Journal:  Eur J Pediatr       Date:  2006-12-14       Impact factor: 3.183

3.  Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets.

Authors:  Miroslav Zivičnjak; Dirk Schnabel; Heiko Billing; Hagen Staude; Guido Filler; Uwe Querfeld; Marius Schumacher; Anke Pyper; Carmen Schröder; Jürgen Brämswig; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2010-12-01       Impact factor: 3.714

Review 4.  Congenital Conditions of Hypophosphatemia Expressed in Adults.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2020-05-14       Impact factor: 4.333

5.  Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients.

Authors:  Sean DeLacey; Ziyue Liu; Andrea Broyles; Sarah A El-Azab; Cristian F Guandique; Benjamin C James; Erik A Imel
Journal:  Bone       Date:  2019-07-02       Impact factor: 4.398

6.  Urinary prostaglandins and the effect of indomethacin on phosphate excretion in children with hypophosphatemic rickets.

Authors:  Mouin G Seikaly; Pamela G Waber; Michel Baum
Journal:  Pediatr Res       Date:  2008-08       Impact factor: 3.756

Review 7.  X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.

Authors:  Giampiero Igli Baroncelli; Stefano Mora
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-06       Impact factor: 5.555

Review 8.  Vitamin D Metabolites: Analytical Challenges and Clinical Relevance.

Authors:  N Alonso; S Zelzer; G Eibinger; M Herrmann
Journal:  Calcif Tissue Int       Date:  2022-03-03       Impact factor: 4.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.